bluebird bio, Inc. (NASDAQ:BLUE) CEO Nick Leschly sold 2,127 shares of bluebird bio stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $145.17, for a total transaction of $308,776.59. Following the transaction, the chief executive officer now owns 257,486 shares of the company’s stock, valued at $37,379,242.62. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Nick Leschly also recently made the following trade(s):

  • On Friday, October 20th, Nick Leschly sold 3,350 shares of bluebird bio stock. The shares were sold at an average price of $145.02, for a total transaction of $485,817.00.
  • On Monday, October 23rd, Nick Leschly sold 7,050 shares of bluebird bio stock. The shares were sold at an average price of $145.14, for a total transaction of $1,023,237.00.
  • On Tuesday, October 17th, Nick Leschly sold 10,823 shares of bluebird bio stock. The shares were sold at an average price of $145.05, for a total transaction of $1,569,876.15.
  • On Friday, September 1st, Nick Leschly sold 46,833 shares of bluebird bio stock. The shares were sold at an average price of $122.27, for a total transaction of $5,726,270.91.
  • On Wednesday, August 30th, Nick Leschly sold 25,667 shares of bluebird bio stock. The shares were sold at an average price of $115.18, for a total transaction of $2,956,325.06.

bluebird bio, Inc. (NASDAQ:BLUE) traded up $13.30 during trading hours on Friday, reaching $156.25. 1,240,575 shares of the company’s stock were exchanged, compared to its average volume of 816,660.

bluebird bio (NASDAQ:BLUE) last issued its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported ($1.73) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.68) by ($0.05). The business had revenue of $7.71 million for the quarter, compared to analysts’ expectations of $8.47 million. bluebird bio had a negative return on equity of 28.79% and a negative net margin of 883.18%. The company’s revenue was up 397.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($2.07) EPS. equities analysts predict that bluebird bio, Inc. will post -6.78 earnings per share for the current year.

WARNING: This story was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this story on another website, it was stolen and republished in violation of United States & international copyright and trademark law. The legal version of this story can be read at https://www.americanbankingnews.com/2017/11/03/bluebird-bio-inc-blue-ceo-sells-308776-59-in-stock.html.

Several research firms have recently issued reports on BLUE. Jefferies Group LLC reiterated a “buy” rating and set a $88.00 target price on shares of bluebird bio in a report on Friday, August 11th. Zacks Investment Research lowered shares of bluebird bio from a “buy” rating to a “hold” rating in a report on Tuesday, July 18th. BidaskClub lowered shares of bluebird bio from a “hold” rating to a “sell” rating in a report on Wednesday, August 2nd. Morgan Stanley raised shares of bluebird bio from an “underweight” rating to an “equal weight” rating in a research report on Friday. Finally, Evercore ISI raised shares of bluebird bio from an “in-line” rating to an “outperform” rating and set a $102.00 price target for the company in a research report on Monday, October 16th. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and fourteen have assigned a buy rating to the stock. bluebird bio presently has an average rating of “Buy” and a consensus target price of $131.05.

Institutional investors have recently modified their holdings of the company. Quantitative Investment Management LLC boosted its stake in shares of bluebird bio by 1,193.8% during the 2nd quarter. Quantitative Investment Management LLC now owns 104,800 shares of the biotechnology company’s stock worth $11,009,000 after acquiring an additional 96,700 shares during the last quarter. State of Wisconsin Investment Board purchased a new position in shares of bluebird bio during the 2nd quarter worth $3,257,000. Winfield Associates Inc. boosted its stake in shares of bluebird bio by 6.1% during the 2nd quarter. Winfield Associates Inc. now owns 2,822 shares of the biotechnology company’s stock worth $296,000 after acquiring an additional 162 shares during the last quarter. OMERS ADMINISTRATION Corp purchased a new position in shares of bluebird bio during the 2nd quarter worth $1,061,000. Finally, Janus Henderson Group PLC purchased a new position in shares of bluebird bio during the 2nd quarter worth $5,252,000.

About bluebird bio

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Insider Buying and Selling by Quarter for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.